Focus::NGS™ – Access the Next-Generation of Cancer Diagnostics

Posted on: Thursday, December 4th, 2014

Focus::NGS – CGI’s Unique, Targeted NGS Panel

One of the major challenges in doing cancer diagnostics is to find mutations that might be very important, but might be present in very low levels in the tumor due to tumor heterogeneity.

Two problems facing the traditional sequencing assay are sensitivity and throughput. By sensitivity what I mean is that there will be mutations present at a very low level such that they will not be detected and by throughput what I mean is that you can only look at a very small number of genes each time such that you will not have a very comprehensive view of the genomic profile of a tumor.

The next generation sequencing service enables us to meet the challenges of these two problems by giving us the chance to look at multiple genes simultaneously at a highly sensitive level. The NGS service offered at CGI will then help the clinicians in patient management at multiple levels such as diagnosis, prognosis, and treatment selection.

Ultimately, based on the NGS result, each patient will receive the most suitable treatment tailored for himself or herself, which is the essence of personalized medicine.

Click here to learn more about Focus::NGS™

Filed Under:
Tags: ,

> Additional Articles
> Join Our Mailing List


Additional Videos»

  • Cancer Genetics offers the FDA-approved DAKO PD-L1 IHC 22C3 pharmDx companion diagnostic test for KEYTRUDA®

    The FDA approved PD-L1 (IHC) 22C3 pharmDx companion diagnostic test for  KEYTRUDA® (pembrolizumab)​ is now available at CGI to assess PD-L1 expression in Non-Small Cell Lung Cancer

  • Cancer Genetics is a center of excellence for oncology-focused clinical trials.

    Narasimha Marella, Ph.D., Corporate Development Manager speaks about how Cancer Genetics can help biopharma companies overcome oncology-focused clinical trial challenges. The current challenge that is faced by biotech and biopharmas that are involved in oncology drug development is their ability to accurately stratify and randomize patients for their clinical trials based on biomarkers. Despite the […]

  • Cancer Genetics offers an integrated solution for clinical trials.

    Kristen Hopp, PMP, Senior Clinical Trial Project Associate speaks about Cancer Genetics integrated clinical trial services. In hematological malignancies one of the challenges is the diversity of subtypes.  For these trials, genomic insights have become critically important.  Our innovative research and our clinical expertise in these cancers makes CGI an ideal partner for these clinical […]

  • Cancer Genetics offers an integrated solution for Clinical Trials.

    Nathan Campbell, Director of Clinical Services speaks about Cancer Genetics’ Biorepository capability and how having access to samples genomic data is important. As a clinical trial progresses and a more diverse patient population is recruited, variations in a drug’s efficacy and safety can start to arise. Unexpected adverse events can potentially kill a drug at […]

See All Videos Back to Top